mediastinal involvement or prognosis.
In non-Hodgkin patients a poor prognosis was generally associated with low SACE activity. The low SACE activity was not related to recent corticosteroid treatment, and the cause and pathophysiological significance is unexplained.
Since SACE is high in the granulomatous disorder sarcoidosis (which can mimic malignant lymphnode and blood diseases) SACE analysis can be valuable in evaluating patients with mediastinal lymphadenopathy and those in whom noncaseating epithelioid granulomas are found.
ANGIOTENSIN -CONVERTING ENZYME (ACE, kininase II) is a membrane-bound glycoprotein which converts angiotensin I to angiotensin II, and participates in bradykinin degradation. Although the enzyme is always found in endothelial cells, the greatest amount and activity occurs in the endothelium of lungs (Soffer, 1976) .
In the granulomatous multisystem disease sarcoidosis, serum-ACE (SACE) has been found to be high (Lieberman, 1975; Silverstein et al., 1977) . The finding of a high ACE activity in sarcoid lymph nodes (Silverstein et al., 1976) and the demonstration of ACE in sarcoidosis epithelioid cells (Silverstein et al., 1979) point to the monocyte-macrophagederived epithelioid-cell granuloma as the source of high SACE in sarcoidosis.
The reasons for investigating SACE in malignant lymphomas, leukaemia and multiple myeloma were: Diagnostic. In subacute sarcoidosis hilar and mediastinal lymphnode enlargement with or without pulmonary infiltrations are typical; but a similar picture can in fact also be caused by malignant diseases. Furthermore, non-caseating granulomas may be seen in up to 20% of patients with Hodgkin's disease (Neiman, 1977; Whittaker et al., 1978) .
Pathophysiological. Sarcoidosis and
Hodgkin's disease share some common features: granuloma formation, impairment of delayed immune reactions (Chase, 1966) , monocyte activation (Kitahara et al., 1979; Douglas et al., 1976) and increased production of leucocyte-migration inhibitory factors (MIF; Yoshida et al., 1 979).
Furthermore, coexistent sarcoidosis and Hodgkin's disease has been described (Goldfarb & Cohen, 1970) and it has been proposed that malignant lymphomas occur more frequently among sarcoidosis patients than expected (Brincker & Wilbek, 1974) although recent evidence speaks against this (R0mer, 1980b) . We therefore found it appropriate to examine a series of Hodgkin's disease patients, as the main purpose of the study. Additionally, patients with non-Hodgkin lymphoma, leukaemia and multiple myeloma were examined for comparison, because all these diseases affect the lymphoproliferative and reticulo-endothelial systems.
MATERIALS AND METHODS
Patients.-The series consisted of 96 patients (Table I ). All underwent routine investigation including haematological and biochemical profile, marrow aspiration and X-ray examination of the lungs. Patients with malignant lymphomas were subjected to lymphangiography, liver and bone scans. In many cases of Hodgkin's disease, explorative laparotomy was performed. All patients had normal kidney function.
Patients with Hodgkin's disease were staged according to the Ann Arbor International Convention (Carbone et al., 1971) .
"Treated" patients were under treatment with prednisone and/or cytostatics at examination, or had stopped treatment less than 2 months before. This limit was chosen because the primary aim of the study was to examine the influence on enzyme activity of the disease itself. Some patients received large intermittent doses of steroid therapy and it was necessary to choose a relatively long period free of medication before we could state that a given patient was "without treatment". SACE analysis.-The analysis was performed by the spectrophotoinetric method described by Cushman & Cheung (1971) as modified by Lieberman (1975) and including the correction factor reported later (Lieberman, 1976 (Table II) . No differences between the subgroups were significant.
In the whole series only one patient (with Hodgkin's disease) had a slightly raised SACE (39-2 u/ml) on one occasion. At re-examination 2 months later, SACE was in the higher normal range (34.0 u/ml).
The only patient in whom non-caseating epitheloid granulomas were found had normal SACE. Similar analyses in the 69 patients with non-Hodgkin malignant diseases produced no consistent pattern, except in respect of prognosis. Especially, no significant difference was found whether or not the patients were recently treated with prednisone (e.g. actually being treated or treated within 2 months of examination); SACE was 19-1 u/ml + 6-6 in 23 patients in prednisone treatment and 21-2 u/ml+ 6-8 in 46 patients not receiving prednisone.
Furthermore, there was no difference in SACE between acute and chronic leukaemia, or between leukaemias of myeloid or lymphoid origin.
As mentioned above, mean SACE was and with a near-normal SACE (mean 22-0 u/ml, range 14-6-27-6).
We therefore examined the relationship between SACE activity and mortality over 3 and 12 months in non-Hodgkin patients, to determine whether low SACE was related to poor prognosis in general.
The results are shown in Table IV . Regarding the whole series, mean SACE was significantly lower in patients who expired within 3 months than in the surviving patients. Furthermore, in patients with chronic leukaemia and multiple myeloma who died within 3 months and 12 months respectively, all had a significantly lower enzyme activity than survivors.
Amongst all patients with SACE below the normal range (12-0 u/ml) there was a significantly higher mortality after 3 months and one year than in other patients (Table V) 
18-9+5-8
(1 )
Outcome after one year
21-2 + 6-9
21-8 + 7-6 (6)
n.s.
n.s. 17-1 + 6 0
19-5 + 6-2
22-0 + 6-9
P<0-01 13-4+5-1 19-4+6-0 The results of the present paper contrast with the high SACE reported in sarcoidosis, and they underline the difference between the nature of sarcoidosis and, for example, Hodgkin's disease. In sarcoidosis, the frequency of high SACE has been reported from 29% (Turton et al., 1979) to about 60% (Lieberman et al., 1979) (Lieberman & Beutler, 1976) whereas SACE is decreased in lung cancer (Silverstein et al., 1977; Lieberman et al., 1979) and untreated tuberculosis (Romer, 1980a) . For leprosy the results are contradictory (Studdy et al., 1978; Lieberman et al., 1979) .
The lack of non-significance of the lower SACE among prednisone-treated patients does not contradict other reports on a generally low SACE in steroid-treated nonsarcoid patients (Turton et al., 1979) . The non-significance may be because the "prednisone-treated" patients in the present series included patients who had stopped treatment with prednisone within 2 months.
Furthermore, the results suggest that SACE analysis may be helpful in evaluating patients with mediastinal and hilar masses, and may give valuable information when non-caseating epitheloid granulomas are found.
An explanation for the low SACE in the malignant diseases examined cannot be given at present. The difference in SACE between moderately healthy and extremely ill myeloma patients, and the relationship between SACE level and mortality in chronic leukaemia suggest that perhaps enzyme production is reduced in the terminal stage of disease.
We can conclude that SACE is generally low in the diseases examined, but without a consistent pattern. The greatest clinical value of SACE analysis in this context is as a supplement to other methods of evaluating patients with intrathoracic lymphnode enlargement and in diagnosis and monitoring of patients with sarcoidosis.
